Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Soleno Therapeutics, Inc. (SLNO) had Revenue of $91.73M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$91.73M
Net Income	$42.94M
Cost of Goods Sold	$0.86M
Gross Profit	$90.87M
Operating Expenses	$52.15M
Operating Income	$39.58M
Non-Operating Income/Expense	$3.78M
Pre-Tax Income	$43.36M
Normalized Pre-Tax Income	$43.36M
Income after Taxes	$43.36M
Income from Continuous Operations	$43.36M
Consolidated Net Income/Loss	$43.36M
Normalized Income after Taxes	$43.36M
EBIT	$39.58M
EBITDA	$40.09M
Weighted-Average Shares Outstanding (Basic)	50.82M
Weighted-Average Shares Outstanding (Diluted)	52.38M
Earnings per Share (EPS) (Basic)	$0.95
Earnings per Share (EPS) (Diluted)	$0.96
Balance Sheet Financials
Current Assets	$355.81M
Property, Plant, and Equipment	$0.18M
Long-Term Assets	$208.02M
Total Assets	$563.83M
Current Liabilities	$61.36M
Long-Term Debt	$49.86M
Long-Term Liabilities	$52.35M
Total Liabilities	$113.72M
Common Equity	$450.12M
Tangible Shareholders Equity	$445.25M
Shareholders Equity	$450.12M
Common Shares Outstanding	52.29M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$46.80M
Cash Flow from Investing Activities	$-201.78M
Cash Flow from Financial Activities	$137.16M
Beginning Cash	$87.93M
End Cash	$70.11M
Increase/Decrease in Cash	$-17.82M
Stock-Based Compensation	$45.85M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.80
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.10
Debt to Equity Ratio	0.11
Gross Margin	99.06%
Operating Margin	43.15%
EBIT Margin	43.15%
EBITDA Margin	--
Pre-Tax Profit Margin	47.27%
Profit Margin	46.81%
Free Cash Flow	$46.73M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.16
Inventory Turnover	0.06
Receiveable Turnover	3.25
Days Sales in Receivables	27.68
Return on Equity	9.63%
Return on Tangible Equity	9.74%
Return on Assets	7.69%
Return on Investments	8.67%
Book Value Per Share	$8.61
Free Cash Flow per Share	$0.89
Operating Cash Flow per Share	$0.89

Data from Zacks Investment Research, Inc.